Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells
dc.authorid | Tezcanli Kaymaz, Burcin/0000-0003-1832-1454 | |
dc.authorid | Celik, Besne/0000-0001-5417-8005 | |
dc.contributor.author | Tezcanli Kaymaz, Burcin | |
dc.contributor.author | Gumus, Nurcan | |
dc.contributor.author | Celik, Besne | |
dc.contributor.author | Alcitepe, Ilayda | |
dc.contributor.author | Biray Avci, Cigir | |
dc.contributor.author | Aktan, Cagdas | |
dc.date.accessioned | 2024-08-31T07:50:05Z | |
dc.date.available | 2024-08-31T07:50:05Z | |
dc.date.issued | 2024 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | Chronic myeloid leukemia (CML) is a clonal myeloproliferative hematological disease characterized by the chimeric breakpoint-cluster region/Abelson kinase1 (BCR | en_US |
dc.identifier.doi | 10.1089/jir.2023.0170 | |
dc.identifier.endpage | 189 | en_US |
dc.identifier.issn | 1079-9907 | |
dc.identifier.issn | 1557-7465 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 38579140 | en_US |
dc.identifier.scopus | 2-s2.0-85190333642 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 178 | en_US |
dc.identifier.uri | https://doi.org/10.1089/jir.2023.0170 | |
dc.identifier.uri | https://hdl.handle.net/11454/105111 | |
dc.identifier.volume | 44 | en_US |
dc.identifier.wos | WOS:001197190100002 | en_US |
dc.identifier.wosquality | N/A | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Mary Ann Liebert, Inc | en_US |
dc.relation.ispartof | Journal of Interferon and Cytokine Research | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.snmz | 20240831_U | en_US |
dc.subject | Ponatinib | en_US |
dc.subject | Combination Therapy | en_US |
dc.subject | Cytokines | en_US |
dc.subject | Stat5 Inhibitor Pimozide | en_US |
dc.subject | Drug Resistance | en_US |
dc.title | Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells | en_US |
dc.type | Article | en_US |